EOLS stock forecast, quote, news & analysis
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market... Show more
Evolus (EOLS) Stock Analysis: Portfolio Expansion and the Path to Sustainable Profitability
Key Takeaways
- Evolus shares traded near $7.40 in recent sessions, a modest pullback from the roughly $9.30 peak reached in early September.
- Over the trailing 30 days the stock moved only modestly lower — well within a single-digit range — after a strong post-earnings rally earlier in the quarter.
- The company posted its third consecutive quarter of positive Adjusted EBITDA and raised its full-year 2026 revenue outlook.
- Evolus is diversifying beyond its flagship Jeuveau neurotoxin into dermal fillers and skin-quality injectables.
- Tariff uncertainty tied to Jeuveau's South Korean manufacturing remains a key risk investors are watching.
Current Market Snapshot
Evolus, Inc. (EOLS) has traded in a wide range in recent months. After bottoming in the mid-$5 range in mid-July, the stock surged following its second-quarter results, climbing to an intraday high near $9.30 in early September. Since then, shares have retraced into the low-$7 range, reflecting a measured cooling of momentum rather than a sharp single-session move. Over the most recent 30-day window, the stock has drifted only modestly lower, leaving its longer-term trend intact but signaling a period of consolidation below the recent highs.
Evolus (EOLS) Business Overview and Competitive Position
Evolus is a performance beauty company operating in the cash-pay medical aesthetics market across the United States, Canada, Europe, and Australia. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator used to treat frown lines and competes directly with AbbVie's Botox. The company has historically built its brand around digital-first marketing and loyalty programs aimed at younger, image-conscious consumers.
Beyond Jeuveau, Evolus has been broadening its portfolio. It commercializes the Evolysse line of hyaluronic acid (HA) dermal fillers in the U.S. and the Estyme collection in Europe, and it holds an exclusive U.S. agreement with IBSA to commercialize Profhilo, a skin-quality injectable. This diversification away from a single-product toxin franchise is central to the company's long-term growth strategy and a key reason investors follow the stock.
Recent Developments Driving EOLS
Evolus's second-quarter 2026 results, reported in early August, were the defining catalyst of the recent period. Global net revenue reached $84.1 million, up 21% year over year, and the company delivered its third consecutive quarter of positive Adjusted EBITDA at $4.7 million. Management raised the lower end of its full-year 2026 revenue guidance to a range of $330 million to $337 million and lifted its adjusted gross margin outlook to 67.0% to 67.5%.
The company also advanced its portfolio expansion, launching the full Estyme collection across Europe, signing a licensing agreement with Symatese to bring Estyme to Canada, Australia, and New Zealand, and entering the exclusive U.S. Profhilo agreement with IBSA. These moves reinforce the shift toward a multi-product model, though their revenue contributions are weighted toward later years.
Offsetting this progress, tariff uncertainty has weighed on sentiment. Following an April announcement of a 15% tariff on patented pharmaceuticals from South Korea, Jeuveau — manufactured by a South Korean partner — could face new duties absent an exception. Evolysse, classified as a medical device imported from France, is subject to a separate 10% tariff. The company has indicated it has flexibility to mitigate the near-to-medium-term impact given Jeuveau's three-year shelf life, but the issue remains a focus for the market.
Trending AI Robots
For traders seeking a data-driven approach to opportunities in names like Evolus and across the broader market, Tickeron's Trending AI Robots page offers a curated view of the platform's algorithmic trading strategies. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section. Each bot differs in strategy, timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum to longer-horizon trend following. Exploring the section can help investors understand how systematic, rules-based trading is applied across different market conditions.
2026 Outlook and What Investors Should Watch
Looking ahead, Evolus's trajectory hinges on execution across several fronts. The company's 2026 guidance calls for revenue of $330 million to $337 million, representing roughly 10% to 13% growth, with Evolysse and Estyme injectable gels expected to contribute 10% to 12% of total revenue. Management is targeting a low- to mid-single-digit Adjusted EBITDA margin for the year and has outlined a 2028 long-term outlook of $450 million to $500 million in revenue with 13% to 15% Adjusted EBITDA margins.
Key catalysts to monitor include the anticipated U.S. Food and Drug Administration approval of Evolysse Sculpt in the fourth quarter of 2026 — a product currently excluded from guidance — as well as the ongoing ramp of the filler and Estyme franchises. Investors should also track tariff developments affecting Jeuveau and Evolysse, the pace of customer account growth and reorder rates, and the company's cash position, which stood at $45.2 million as of mid-2026. The path to sustained GAAP profitability and continued operating-leverage gains will be central to whether the stock can build on its recent progress.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EOLS's RSI Indicator climbs out of oversold territory
The RSI Indicator for EOLS moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 29 of the 34 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 63 cases where EOLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +0.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where EOLS advanced for three days, in 209 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
EOLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EOLS as a result. In 65 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
EOLS moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EOLS crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EOLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EOLS entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-15.838) is normal, around the industry mean (10.407). P/E Ratio (-13.981) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (1.646) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. EOLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EOLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of neurotoxins
Industry PharmaceuticalsGeneric